Clinical Failure (children with a severe to moderate overall clinical assessment score at two hours) · patients with acute asthma
IV + inhaled beta agonist probably leads to lower clinical Failure (children with a severe to moderate overall… compared with inhaled beta‐agonist (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age compared with systemic steroids (moderate certainty).
2 findings from 1 review
Diastolic blood pressure > 95th percentile at 7 years · Neonates with developing BPD
Inhaled steroids probably leads to lower diastolic blood pressure > 95th percentile at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Ever diagnosed as asthmatic by 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in ever diagnosed as asthmatic by 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Neonates with developing BPD
Inhaled steroids showed no clear difference in BPD at 36 weeks' postmenstrual age compared with systemic steroids (low certainty).
1 finding from 1 review
Hyperglycaemia · Neonates with developing BPD
Inhaled steroids showed no clear difference in hyperglycaemia compared with systemic steroids (low certainty).
1 finding from 1 review
Hypertension · Neonates with developing BPD
Inhaled steroids may leads to lower hypertension compared with systemic steroids (low certainty).
1 finding from 1 review
General conceptual ability (GCA) score at 7 years The test has a standardisation mean of 100 and SD of 15 · Neonates with developing BPD
Inhaled steroids showed no clear difference in general conceptual ability (GCA) score at 7 years The test has a… compared with systemic steroids (moderate certainty).
1 finding from 1 review
Moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Death or moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Systolic blood pressure > 95th percentile at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in systolic blood pressure > 95th percentile at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age among all randomised compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Death or BPD (28 days) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 36 weeks' postmenstrual age compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
BPD at 28 days · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Annual Exacerbation Rates · people with bronchiectasis
Inhaled mannitol showed no clear difference in exacerbations Exacerbation rate per year. compared with placebo (moderate certainty).
1 finding from 1 review
Hospitalisations Number of participants experiencing one of more hospitalisations. · people with bronchiectasis
Inhaled mannitol showed no clear difference in hospitalisations Number of participants experiencing one of more… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · people with bronchiectasis
Inhaled mannitol showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with bronchiectasis
Inhaled mannitol showed no clear difference in health‐related quality of life measured on the SGRQ Scale from 0 to… compared with placebo (moderate certainty).
1 finding from 1 review